Targeting ornithine decarboxylase (ODC) inhibits esophageal squamous cell carcinoma progression.
Targeting ornithine decarboxylase (ODC) inhibits esophageal squamous cell carcinoma progression.
复制标题
靶向鸟氨酸脱羧酶(ODC)抑制食管鳞状细胞癌进展。
DOI:
10.1038/s41698-017-0014-1
复制
发表时间:
2017
影响因子:
7.9
通讯作者:
Dong Z
中科院分区:
文献类型:
--
作者:
He W;Roh E;Yao K;Liu K;Meng X;Liu F;Wang P;Bode AM;Dong Z
To explore the function of ornithine decarboxylase in esophageal squamous cell carcinoma progression and test the effectiveness of anti-ornithine decarboxylase therapy for esophageal squamous cell carcinoma. In this study, we examined the expression pattern of ornithine decarboxylase in esophageal squamous cell carcinoma cell lines and tissues using immunohistochemistry and Western blot analysis. Then we investigated the function of ornithine decarboxylase in ESCC cells by using shRNA and an irreversible inhibitor of ornithine decarboxylase, difluoromethylornithine. To gather more supporting pre-clinical data, a human esophageal squamous cell carcinoma patient-derived xenograft mouse model (C.B-17 severe combined immunodeficient mice) was used to determine the antitumor effects of difluoromethylornithine in vivo. Our data showed that the expression of the ornithine decarboxylase protein is increased in esophageal squamous cell carcinoma tissues compared with esophagitis or normal adjacent tissues. Polyamine depletion by ODC shRNA not only arrests esophageal squamous cell carcinoma cells in the G2/M phase, but also induces apoptosis, which further suppresses esophageal squamous cell carcinoma cell tumorigenesis. Difluoromethylornithine treatment decreases proliferation and also induces apoptosis of esophageal squamous cell carcinoma cells and implanted tumors, resulting in significant reduction in the size and weight of tumors. The results of this study indicate that ornithine decarboxylase is a promising target for esophageal squamous cell carcinoma therapy and difluoromethylornithine warrants further study in clinical trials to test its effectiveness against esophageal squamous cell carcinoma. Blocking an enzyme involved in the cellular synthesis of essential compounds called polyamines could help treat esophageal cancer. Zigang Dong from the University of Minnesota’s Hormel Institute, USA, and colleagues showed that this enzyme, called ornithine decarboxylase (ODC), is expressed at elevated levels in tumor tissues taken from patients with esophageal squamous cell carcinoma. The researchers blocked ODC activity in esophageal cancer cells using either RNA interference techniques or a drug called difluoromethylornithine (DFMO). In both cases, the treatment suppressed further growth and induced cell death. DFMO treatment also reduced the size and weight of tumors in mice implanted with human patient-derived esophageal cancer tissue. The findings point DFMO, which is already used as a medication to treat African sleeping sickness and excessive hair growth, as a potential therapy for cancer patients.
登录
查看更多内容
影响因子:
3.7
作者:
FREDLUND, JO;JOHANSSON, MC;OREDSSON, SM
通讯作者:
OREDSSON, SM
影响因子:
56.9
作者:
Bunz, F;Dutriaux, A;Vogelstein, B
通讯作者:
Vogelstein, B
影响因子:
3.5
作者:
Hayes CS;DeFeo-Mattox K;Woster PM;Gilmour SK
通讯作者:
Gilmour SK
DOI:
10.1073/pnas.90.16.7804
发表时间:
1993-08-15
影响因子:
11.1
作者:
BELLOFERNANDEZ, C;PACKHAM, G;CLEVELAND, JL
通讯作者:
CLEVELAND, JL
DOI:
10.1073/pnas.95.9.4997
发表时间:
1998-04-28
影响因子:
11.1
作者:
Jürgensmeier, JM;Xie, ZH;Reed, JC
通讯作者:
Reed, JC